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Abstract 
Background: V600BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically 
targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibi‑
tors (BRAFi + MEKi). Although the combination therapy has been shown to provide superior clinical benefits, acquired 
resistance is still prevalent and limits the overall survival benefits. Recent work has shown that oncogenic changes can 
lead to alterations in tumor cell metabolism rendering cells addicted to nutrients, such as the amino acid glutamine. 
Here, we evaluated whether melanoma cells with acquired resistance display glutamine dependence and whether 
glutamine metabolism can be a potential molecular target to treat resistant cells.
Methods: Isogenic BRAFi sensitive parental V600BRAF mutant melanoma cell lines and resistant (derived by chronic 
treatment with vemurafenib) sub‑lines were used to assess differences in the glutamine uptake and sensitivity to 
glutamine deprivation. To evaluate a broader range of resistance mechanisms, isogenic pairs where the sub‑lines 
were resistant to BRAFi + MEKi were also studied. Since resistant cells demonstrated increased sensitivity to glutamine 
deficiency, we used glutaminase inhibitors BPTES [bis‑2‑(5 phenylacetamido‑1, 2, 4‑thiadiazol‑2‑yl) ethyl sulfide] and 
L–L‑DON (6‑Diazo‑5‑oxo‑l‑norleucine) to treat MAPK pathway inhibitor (MAPKi) resistant cell populations both in vitro 
and in vivo.
Results: We demonstrated that MAPKi‑acquired resistant cells uptook greater amounts of glutamine and have 
increased sensitivity to glutamine deprivation than their MAPKi‑sensitive counterparts. In addition, it was found that 
both BPTES and L‑DON were more effective at decreasing cell survival of MAPKi‑resistant sub‑lines than parental cell 
populations in vitro. We also showed that mutant NRAS was critical for glutamine addiction in mutant NRAS driven 
resistance. When tested in vivo, we found that xenografts derived from resistant cells were more sensitive to BPTES or 
L‑DON treatment than those derived from parental cells.
Conclusion: Our study is a proof‑of‑concept for the potential of targeting glutamine metabolism as an alternative 
strategy to suppress acquired MAPKi‑resistance in melanoma.
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Background
Melanoma is one of the most aggressive forms of skin 
cancer affecting an estimated 76,100 individuals per year 
and accounting for approximately 9,710 deaths in 2014 
[1, 2]. According to the American Cancer Society, inci-
dents of melanoma have been increasing steadily for the 
past 30 years [2]. Oncogenic mutations in the BRAF gene, 
encoding a serine threonine kinase that is an essential part 
of the RAS–RAF–MEK–ERK signaling cascade have been 
found in approximately 50–70% of metastatic melanoma 
[1, 3]. The mutation in BRAF is frequently found at residue 
600 with valine to glutamic acid (V600EBRAF) and leads to 
a hyperactive BRAF kinase which results in uncontrolled 
cell proliferation and oncogene addiction [1, 4, 5].
Single agent inhibition of the BRAF kinase with small 
molecule inhibitors such as vemurafenib (PLX4032) and 
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dabrafenib, or double-drug combinations of a BRAF 
inhibitor with an inhibitor of MEK1/2 such as cobi-
metinib and trametinib have been successively shown 
to improve patient survival [6–11]. However, even with 
the superior efficacy of the double-drug combination, 
disease control is often cut short by the development of 
acquired resistance. Genetic resistance mechanisms most 
commonly result in reactivation of the MAPK pathway 
through NRAS or KRAS mutations, V600E/KBRAF amplifi-
cation or alternative splicing [5, 12, 13]. In contrast non-
genetic resistance mechanisms often result in MAPK 
pathway-redundant survival with up-regulated expres-
sion of receptor tyrosine kinases such as PDGFRβ [5, 
12–14].
It has recently been shown that tumor cell metabolism 
can be exploited to treat cancer [15]. In the 1920s, Otto 
Warburg found that cancer cells consume very high rates 
of glucose and secrete large amounts of lactate in the 
presence of oxygen, deemed the “Warburg Effect” [15]. 
This inefficient consumption was designed to meet the 
biosynthetic and energy production requirements that 
are frequently seen in tumor cells [16]. It has been shown 
that in addition to glucose, some cancer cells exhibit 
“glutamine addiction” to support the anabolic processes 
that stimulate cell proliferation [17]. Glutamine has been 
shown to be an essential provider of nitrogen for nucleo-
tide and protein synthesis and affect a critical regulator 
of protein translation, the mammalian target of rapamy-
cin complex (mTORC)1 [17]. Studies have also pointed at 
oncogenic changes that allow for regulation of glutamine 
metabolism in cancer cells. For example oncogenic c-myc 
has been implicated in the transcriptional regulation of 
high affinity glutamine transporters to promote glutami-
nolysis [17]. Pancreatic ductal adenocarcinoma (PDAC) 
cells have also been shown to be strongly dependent on 
glutamine and this reprogramming of glutamine metabo-
lism was found to be driven by transcriptional up-regu-
lation of key metabolic enzymes mediated by oncogenic 
KRAS [18]. In melanoma, it has been shown that glu-
tamine transporter ASCT2 was upregulated in V600EBRAF 
mutant melanoma and played a critical role in glutamine 
uptake and cell proliferation [19]. Therefore, it is highly 
plausible that disruption of glutamine metabolism can be 
utilized as a therapeutic approach to treat tumors.
The findings that cancer cells are addicted to glu-
tamine led to therapeutic approaches aimed at impair-
ing glutamine metabolism. Recent work on inhibitors 
that target glutaminase, the enzyme that catalyzes the 
conversion of l-glutamine to l-glutamate and ammo-
nia, suggests significant therapeutic potential for can-
cer treatment. For example, 6-diazo-5-oxo-1-norleucine 
(L-DON), targets glutaminase on its active site to inhibit 
tumor growth [20–22]. Another glutaminase inhibitor, 
bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl 
sulfide (BPTES), and its analogs significantly diminish 
growth of tumor xenografts in  vivo and proliferation of 
cancer cells in  vitro for several tumor types, including 
lymphomas, breast cancers, and gliomas [23–27].
In this study, we demonstrate that melanoma resist-
ant cells uptake glutamine at a higher rate and are more 
sensitive to glutamine starvation than their vemurafenib 
sensitive counterparts. Moreover, we show that glutami-
nase inhibitors BPTES and L-DON can be used to effec-
tively treat resistant cells in vitro and can be used to treat 
tumors in vivo. We propose targeting glutamine metabo-
lism can be used as an alternative treatment strategy to 
target tumors resistant to vemurafenib.
Methods
Cell culture
Human melanoma parental (vemurafenib sensitive) lines 
were generated as previously described [4]. Briefly, cells 
were established directly from patient biopsies and cul-
tured in RPMI 1640 medium with l-glutamine, 10% 
fetal bovine serum and 1% penicillin, streptomycin, and 
amphotericin [4]. M229 parental was previously char-
acterized as BRAFV600E homozygous and M249 paren-
tal was described as V600EBRAF heterozygous and both 
equally sensitive to vemurafenib-mediated growth inhi-
bition in vitro and in vivo [4]. Cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM) with 10% 
fetal bovine serum (Omega Scientific, Inc) and 4  mM 
l-glutamine (Omega Scientific, Inc).
Vemurafenib (PLX 4032) single drug resistant (SDR) 
sub-lines M249 and M229 with V600EBRAF positive muta-
tions were generated in  vitro by chronic vemurafenib 
exposure [12]. Briefly, M229 parental line was treated 
with PLX4032 at 1  mM every 3  days for 4–6  weeks to 
obtain clonal colonies [12]. PDGFRβ RNA upregulation 
was found to contribute to M229 resistance [12]. M249 
resistant sub-line was derived by successively titrating 
PLX4032 up to 10  mM [12]. M249 resistant sub-line 
was shown to harbor a NRAS(Q61K) activating muta-
tion not present in the parental M249 cell line that was 
shown to contribute to resistance [12]. M249 and M229 
resistant cells were maintained in DMEM with 10% fetal 
bovine serum (Omega Scientific, Inc), 4 Mm l-glutamine 
(Omega Scientific, Inc), and with 1  μM vemurafenib 
(PLX4032) (Plexxikon).
Double BRAF inhibitor (vemurafenib) and MEK 
inhibitor (selumetinib) resistant cell lines were gener-
ated as previously described [28]. Briefly, the M249 
DDR5 double drug resistant cell line (DDR) was gener-
ated by treating M249 parental lines with increments 
of vemurafenib and selumetinib and harbored both 
the mutant V600EBRAF amplification and F129LMEK1 
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mutation [28]. M249 double resistant cells were cul-
tured in the above medium maintained with both 1 μM 
vemurafenib (Plexxikon) and 1 μM selumetinib (Selleck 
chemicals).
Nutrient uptake
Parental and single drug resistant cells were seeded at 
2  ×  105 and 1  ×  105 cells/well, respectively in 6 well 
plates in triplicate and allowed to incubate overnight. 
Media only was also plated as a control for parental 
and resistant cells. At 24 and 48  h upon cells reaching 
60% confluence, cell medium was collected and trans-
ferred to micro-centrifuge tubes and placed in the 
Nova Bioprofiler 100plus Analyzer (Nova Biomedical) 
for measurement of nutrient uptake. In addition, cells 
were counted using the Biorad TC20 automated cell 
counter. Upon measurement, medium only control val-
ues were subtracted from readings and values/cell were 
calculated.
DIMSCAN cell in vitro cytotoxicity assays
M249 and M229 parental, single drug resistant (SDR) 
cells, and M249 DDR5 double drug resistant cells (DDR) 
were seeded at 3,000 cells/well and 2,000 cells/well 
(respectively) in 96 well plates. Cells were allowed to set-
tle overnight prior to treatment. After overnight incuba-
tion, cells were washed with 1× PBS to remove traces of 
medium. Parental cells were treated with either media 
with or without l-glutamine or d-glucose, 10 μM BPTES 
[bis-2-(5 phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl 
sulfide] (LT Pharma, Inc.) or 10  μM L-DON (6-Diazo-
5-oxo-l-norleucine) (Sigma-Aldrich) alone. Single drug 
resistant cells were treated in combination with 1  μM 
vemurafenib. Double drug resistant cells were treated in 
combination with both 1 μM vemurafenib and 1 μM sel-
umetinib. BPTES stock solution was dissolved in DMSO 
to a final working concentration of 10 mM and stored at 
−20°C. L-DON was dissolved in water to a final concen-
tration of 100 mM and also stored at −20°C. DMSO and 
water only controls were added to each well. Cells were 
also treated with media without glutamine or glucose 
containing dialyzed fetal bovine serum (Gemini Scien-
tific). Treated cells were incubated for 24, 48, and 72 h. To 
prepare for DIMSCAN analysis, 0.5% Eosin Y was added 
to spaces between wells on a 96 well plate. A solution of 
fluorescein diacetate (FDA) at 10  mg/ml was added to 
0.5% Eosin Y solution to make a working concentration 
of 40μg/ml to add to cells. After a 20  min incubation, 
cells were scanned for fluorescence using DIMSCAN, a 
fluorescence-based digital image microscopy system [29]. 
Results were analyzed to obtain survival percentage using 
the DIMSCAN data analyzer by DTT (Children’s Hospi-
tal Los Angeles).
Western blots
M249 and M229 parental and single drug resistant cells 
were seeded in 6 cm plates overnight to obtain 60% con-
fluence the following day. Cells were washed with 1× 
PBS. Medium with or without glutamine was added to 
cells. After 24  h, cells were lysed with RIPA buffer and 
protease inhibitors and lysates were run on SDS page 
gels. Gels were transferred to a nitrocellulose membrane 
and probed with anti cleaved-PARP (Cell Signaling Tech-
nology) to assess apoptosis.
AnnexinV/DAPI staining
M249 and M229 cells were plated at 5  ×  104 (paren-
tal) and 4 ×  104 cells (resistant) in 12 well plates. Dou-
ble drug resistant lines were plated at 4 × 104 cells in 12 
well plates. After overnight incubation and reaching 60% 
confluence, cells were stained with flourochrome-conju-
gated Annexin V and propidium iodide using eBioscience 
reagents and Annexin V staining protocol. Cell acquisi-
tion was completed using the 9-color CyAn ADP from 
Beckman Coulter (Miami, FL, USA). Research reported 
in this publication included work performed in the Ana-
lytical Cytometry Core supported by the National Cancer 
Institute of the National Institutes of Health under award 
number P30CA33572. Cells were analyzed using FlowJo 
data analysis software (Ashland, OR, USA).
shRNA knockdown
shRNA lentiviral particles (Sigma) were used to infect 
M249 single drug resistant cells at 50% confluence using 
polybrene (Hexadimethrine bromide) (Sigma). Cells were 
selected for puromycin resistance (Sigma) after 48 h. Bulk 
cell populations were utilized for experiments. Knock-
down efficiency was assessed using quantitative PCR and 
determination of relative mRNA expression of NRAS.
In vivo xenograft model
All animal studies were performed according to approved 
IACUC protocols at the City of Hope Cancer Center. 
Nod Scid Gamma (NSG) mice were injected with 5 × 105 
of M249 parental or single drug resistant cells subcuta-
neously on the right flank. When tumor size reached an 
average of 100 mm3 tumor cell volume, mice were treated 
with 15  mg/kg of BPTES or vehicle control (DMSO) 
every other day through intraperitoneal injection. 
Measurements were taken for tumor length and width. 
Tumor volume (mm3) was calculated by multiplying 
(length  ×  width  ×  width)/2. NCr nude mice (Taconic) 
were injected with 2  ×  106 of M249 single drug resist-
ant cells subcutaneously on the right flank. When tumor 
size reached an average of 100  mm3, they were treated 
bi-weekly with 20  mg/kg of L-DON or vehicle control 
(water).
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Statistical analysis
All in vitro experiments were performed in triplicate and 
repeated a minimum of three times. In the figures, rep-
resentative experiments are shown. Paired t tests were 
done to calculate p values for representative experiments 
using Graphpad software (San Diego, CA, USA). Values 
under p < 0.05 were considered significant.
Results
Vemurafenib resistant cells uptake and use glutamine at a 
higher rate than vemurafenib sensitive cells
We first aimed to assess whether there were any differ-
ences in nutrient uptake between isogenic BRAFi sen-
sitive parental V600BRAF mutant melanoma cell lines 
and single drug resistant (derived by chronic treatment 
with vemurafenib) sub-lines. We found that both M249 
and M229 single drug resistant (SDR) cells had greater 
uptake of glutamine than their parental counterparts 
(Figure  1a). It is also known that glutaminase activity 
generates free ammonia, therefore, we also tested for 
NH4+ production [15]. We found that both M249 and 
M229 single drug resistant cells had greater amounts 
of ammonia production than parental cell populations, 
which is indicative of higher glutamine usage (Figure 1a). 
To exclude the possibility that the resistant cells display 
a general increase in metabolism, we also measured glu-
cose uptake and lactate production in M249 and M229 
parental and single drug resistant cells (Figure  1b). In 
contrast to the glutamine uptake, there were no signifi-
cant differences in glucose uptake and lactate produc-
tion between parental and single drug resistant cells 
(Figure 1b). These data suggest that single drug resistant 
cells may be more dependent on glutamine for growth 
and proliferation than vemurafenib-sensitive (parental) 
cell populations.
Vemurafenib resistant cells are more sensitive to glutamine 
deprivation
In order to test this, we aimed to deprive M249 and 
M229 single drug resistant cells of glutamine and glu-
cose to observe the effects on cell survival. We found 
that both M249 and M229 single drug resistant (SDR) 
populations were more sensitive to glutamine depriva-
tion than glucose deprivation (Figure  2a, b). In addi-
tion, both parental and single drug resistant cells were 
deprived of glutamine and tested for apoptosis by meas-
uring PARP cleavage using Western blot analysis. M249 
and M229 single drug resistant cells both had higher 
levels of PARP cleavage upon glutamine deprivation 
than parental counterparts indicating increased levels 
of apoptosis (Figure 2c, d). In correlation with the West-
ern blot results, there were more apoptotic cells upon 
glutamine deprivation in the M249 single drug resist-
ant line than the parental line measured by Annexin V 
staining (Figure 2e). To further evaluate a broader range 
of resistance mechanisms, melanoma isogenic sub-lines 
with acquired vemurafenib and MEK inhibitor double 
drug resistance (DDR) were also used. We tested the 
double drug resistant (DDR) M249 cell line containing 
both BRAF amplication and MEK1 mutations for sen-
sitivity to glutamine. Similar to the single drug resistant 
lines, the M249 double drug resistant line was found to 
be more sensitive to glutamine deprivation than glu-
cose deprivation (Figure  2f ). In addition, we tested for 
apoptosis via Annexin V staining upon glutamine depri-
vation and found that M249 double drug resistant cells 
were also more sensitive to glutamine deprivation than 
parental counterparts (Figure  2g). These results highly 
suggest that resistant cells are more dependent on glu-
tamine for their survival, and that targeting glutamine 
metabolism with inhibitors aimed at blocking glutamine 
usage may be a way to specifically kill the vemurafenib 
resistant cells.
Vemurafenib resistant cells are more sensitive 
to glutaminase inhibitors
To test whether we can target glutamine metabolism 
to treat resistant cells, we used glutaminase inhibitors, 
BPTES and L-DON to treat both parental and resistant 
cell populations. We then assessed cell survival upon 
treatment and observed whether resistant cell popula-
tions were in fact more sensitive to glutamine uptake. 
We found that, although both parental and single drug 
resistant populations were sensitive to glutaminase 
inhibitors BPTES and L-DON, single drug resistant cells 
in combination with vemurafenib were much more sen-
sitive as demonstrated by reduced cell survival percent-
ages (Figure  3a, b). To further examine whether double 
drug resistant cell lines were also sensitive to glutaminase 
inhibitors, we tested M249 double drug resistant cell line 
for survival after treatment with BPTES. We found that 
the double drug resistant line (similar to the single drug 
resistant line) was more sensitive to BPTES than parental 
counterparts (Figure  3c). To address whether this effect 
required BRAF inhibition or BRAF/MEK1 inhibition, 
we treated both M249 single and double drug resist-
ant cell lines with BPTES and without glutamine in the 
presence or absence of BRAF/MEK inhibitors. We found 
that treatment of single or double drug resistant cell lines 
does not require the presence of the inhibitor to become 
sensitive to glutamine deprivation or BPTES treatment 
(Figure 3d). These results suggest that glutaminase inhib-
itors may be used as a strategy to target resistant cell 
populations.
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Figure 1 Vemurafenib resistant cells uptake and use glutamine at a higher rate than vemurafenib sensitive cells. Melanoma M249 and M229 vemu‑
rafenib sensitive (parental) and single drug resistant (SDR) cell lines were plated to be 60% confluent and medium was changed after overnight 
incubation. Medium only was used as a control. Cells were then cultured for 24 h. Medium was then taken from growing cells and measurements 
were obtained of glutamine uptake, NH4
+ production, glucose uptake, and lactate production using the Nova Bioprofiler 100 plus as described 
in materials and methods. Cells were counted and results are expressed as a glutamine uptake per cell (mmol/L) and NH4
+ production per cell 
(mmol/L) and b glucose uptake per cell (mmol/L) and lactate production per cell (mmol/L) and are representative of the average (±standard devia‑
tion) of triplicate experiments.
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Figure 2 Vemurafenib resistant cells are more sensitive to glutamine deprivation. a Melanoma M249 and b M229 single drug resistant (SDR) 
cells were cultured in the presence of medium with or without glutamine (Gln) or glucose (Gluc). After 24 h representative images and surviving 
fractions (survival %) compared to control cells in complete medium are shown using DIMSCAN, a microcomputer fluorescence‑based cytotoxic‑
ity assay (n = 6, **p < 0.01). Western blot analysis was also used to assess levels of cleaved PARP as an indicator of apoptosis in both c M249 and d 
M229 parental and SDR cell lines. e Apoptosis was also assessed using flow cytometry of M249 parental and resistance cells stained with AnnexinV 
and DAPI. M249 parental and SDR cells were cultured in the presence of medium with and without glutamine for 24 h. Representative dot blots 
and percentages of AnnexinV positive cells are shown. f Melanoma double drug resistant (DDR) cell line M249 DDR5 was cultured in the presence 
of medium with and without glutamine (Gln) or glucose (Gluc). After 24 h representative images and surviving fractions (survival %) compared 
to control cells in complete medium are shown using DIMSCAN, a microcomputer fluorescence‑based cytotoxicity assay (n = 6, ***p < 0.001). g 
Apoptosis was also assessed using flow cytometry of M249 parental and DDR cells stained with AnnexinV and DAPI. M249 parental and DDR cells 
were cultured in the presence of medium with and without glutamine for 24 h. Representative dot blots and percentages of AnnexinV positive cells 
are shown.
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Figure 3 Vemurafenib resistant cells are more sensitive to glutaminase inhibitors. a M249 and M229 parental single drug resistant (SDR) cells 
were cultured in the presence of medium control (DMSO) or 10 μM BPTES for 48 h. SDR cell lines were cultured in combination of vemurafenib 
(1 μM) and BPTES. Surviving cell fraction percentage (survival %) compared to vehicle control (DMSO) was assessed using DIMSCAN technology 
(n = 6, ***p < 0.001, *p < 0.05). b M249 and M229 parental and single drug resistant cells were cultured in the presence of vehicle control (water) 
or 10 μM L‑DON for 48 h. SDR cell lines received a combination of vemurafenib (1 μM) and L‑DON. Surviving cell fraction percentage (survival %) 
compared to vehicle control (DMSO) was assessed using DIMSCAN technology (n = 6, ***p < 0.001, *p < 0.05). c M249 parental and double drug 
resistant (DDR) cells were cultured in the presence of medium control (DMSO) or 10 μM BPTES for 48 h. DDR cell lines were cultured in combination 
with vemurafenib (1 μM), selumetinib (1 μM), and BPTES. Surviving cell fraction percentage compared to vehicle control (DMSO) (survival %) was 
assessed using DIMSCAN technology (n = 6, ***p < 0.001). d M249 single (SDR) and double drug (DDR) resistant lines were cultured in the presence 
or absence of inhibitor (1 μM vemurafenib for SDR and 1 μM vemurafenib and 1 μM selumentib for DDR) and subsequently treated with 10 μM 
BPTES or deprived of glutamine (Gln) for 48 h. Surviving cell fraction percentage compared to vehicle control (DMSO) (survival %) was assessed 
using DIMSCAN technology.
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Knock down of NRAS in vemurafenib resistant cells reduces 
sensitivity to glutaminase inhibitor
To determine whether resistance acquired NRAS muta-
tions had a role in the transformation of M249 resistant 
cells to glutamine dependence, cells with stable knock-
down of NRAS and scrambled shRNA controls were 
prepared using short hairpin RNA (shRNA). First, we 
assessed whether the shRNA was successful at reducing 
levels of NRAS in the cell. Indeed, relative mRNA expres-
sion of NRAS was reduced in shNRAS knockdown cells 
well below control levels (Figure  4a). Control and shN-
RAS knock down cells were subsequently treated with 
BPTES and assessed for cell survival without the pres-
ence of BRAF inhibitor vemurafenib in the medium. We 
found that knocking down NRAS allowed cells to become 
less sensitized to the glutaminase inhibitor BPTES when 
compared to control cell lines (Figure 4b). These results 
suggest that resistance acquired mutations in NRAS con-
tribute to reprogramming of resistant cells to glutamine 
dependence.
Vemurafenib resistant melanoma tumors are sensitive 
to glutaminase inhibitor treatment in vivo
Since in  vitro data demonstrated the potential of glu-
taminase inhibitors to treat resistant cell lines, we asked 
whether these inhibitors would also be effective in vivo. 
To do this, xenograft experiments with NSG mice were 
used to inject mice with both M249 parental (vemu-
rafenib sensitive) and M249 single drug resistant cell 
lines and subsequently treat with glutaminase inhibitor 
BPTES. As shown in Figure 5a, BPTES dramatically sup-
pressed tumor growth in mice injected with M249 single 
drug resistant cells compared to mice injected with the 
parental (sensitive) cells. As the BPTES treatment dis-
played minimal effect on tumor growth from parental 
cells, we next focused to validate whether targeting glu-
tamine metabolism is efficient to inhibit resistant tumor 
growth using a different glutaminase inhibitor, L-DON. 
Similarly, we found that L-DON effectively blocked 
vemurafenib resistant tumor growth (Figure 5b).
Discussion
Here, we demonstrated that M249 and M229 vemu-
rafenib resistant cells have been reprogrammed to 
become increasingly dependent on glutamine when com-
pared to their vemurafenib-sensitive counterparts. In 
addition, we show that acquisition of resistance increased 
sensitivity of these cells to glutamine deprivation. We 
also demonstrated that, in addition to single drug resist-
ant lines, double drug resistant lines harboring both the 
BRAF amplification and MEK1 mutations became sensi-
tive to glutamine deprivation. We were successfully able 
to exploit this sensitivity to glutamine to kill these single 
and double drug resistant cells with a combination of glu-
taminase inhibitors BPTES or L-DON and vemurafenib. 
In both single and double drug resistant cases, decreased 
cell survival was observed. In addition, knocking down 
NRAS in the M249 resistant cells decreased the sensi-
tivity of these cells to both glutaminase inhibitors, indi-
cating the possibility that resistance acquired mutations 
may influence this increased dependence on glutamine. 
These results were also obtained in  vivo as treating 
mice injected with M249 single drug resistant cells with 
Figure 4 Knock down of NRAS in vemurafenib resistant cells reduces 
sensitivity to glutaminase inhibitor. Melanoma M249 resistant cells 
were infected with shNRAS or shControl lentiviral particles and 
selected for puromycin resistance after 48 h. a Quantitative PCR was 
used to measure relative mRNA expression of NRAS in shControl and 
shNRAS infected cells. b shNRAS or shControl cells were cultured in 
the presence of 10 μM BPTES for 48 h or with vehicle control (DMSO). 
Surviving cell fraction percentage (survival %) compared to vehicle 
control (DMSO) was determined using DIMSCAN analysis (n = 6, 
*p < 0.05).
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BPTES or L-DON resulted in a significant decrease of 
tumor volume.
Single agent treatment with BRAF inhibitors such 
as vemurafenib and dabrafenib have demonstrated 
improved survival for patients with V600EBRAF mutant 
melanoma and are currently approved by the US Food 
and Drug Administration for treatment [13]. In addi-
tion, combination therapy of BRAF inhibitors with allos-
teric MEK1 and MEK2 inhibitors are also in clinical 
trials and have been approved for treatment for BRAF 
mutant melanomas [7, 13, 28, 30, 31]. However, as with 
single agent therapies, combination therapy with BRAF 
and MEK inhibitors have also led to the development of 
mechanisms of resistance by further amplifying existing 
resistance mutations or by reactivating the MAPK path-
way [9, 13, 28]. These resistance mechanisms have led to 
the need for alternative treatment options [13]. Recently, 
blocking the immune-regulatory checkpoints that limit 
T cell responses using antagonistic antibodies against 
the programmed death 1 pathway (PD-1) and one of its 
ligands, programmed death ligand 1 (PD-L1), and block-
ade of CTLA-4/B7 (cytotoxic T lymphocyte-associated 
antigen-4) interaction with anti-CTLA-4 antagonistic 
monoclonal antibodies (mAbs) have demonstrated high 
clinical benefits in melanoma patients [32, 33]. Besides 
targeting immuno-responses, whether targeting altered 
metabolism to treat resistant melanoma cells has not 
yet been explored. Our study suggests that inhibition of 
Figure 5 Vemurafenib resistant melanoma tumors are sensitive to glutaminase inhibitor treatment in vivo. a Nod Scid Gamma (NSG) mice were 
injected with 5 × 106 of M249 parental or single drug resistant cells subcutaneously on the right flank. When tumor size reached an average of 
100 mm3 tumor cell volume, treatment with 15 mg/kg of BPTES or vehicle control (DMSO) was provided every other day through intraperitoneal 
injection. Measurements were taken for tumor length and width. Tumor volume (mm3) was calculated by multiplying (length × width × width)/2. 
Graph represents mean tumor volume ± SD. b Nude mice were injected with 2 × 106 of M249 resistant cells subcutaneously on right flank. When 
tumor size reached an average of 100 mm3 tumor cell volume, treatment with 20 mg/kg of L‑DON or vehicle control (water) was provided twice a 
week through intraperitoneal injection. Graph represents mean tumor volume ± SD.
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glutamine metabolism could be a promising way to treat 
single and double resistant tumor types.
As our data suggested that different resistance mod-
els could all lead to “glutamine addiction”, it is critical 
to identify how these cells were able to reprogram to a 
preferential glutamine dependent metabolism. It will be 
important in the future to look at glutamine transport-
ers or metabolic enzymes involved in the glutamine 
metabolic pathway to assess how mutations are directly 
involved in modifying the intrinsic metabolism of these 
cells. This will allow for the development of more tar-
geted therapies that can be used to target tumors that do 
become glutamine dependent.
Overall, these data suggest that both vemurafenib 
single drug resistant and vemurafenib/selumetinib 
(MEK inhibitor) double drug resistant lines are sen-
sitive to glutamine and to glutaminase inhibitors. 
Therefore targeting glutamine metabolism may be a 
useful tool in the future to treat vemurafenib resistant 
melanoma.
Conclusion
Currently, therapy used for the treatment of vemu-
rafenib resistant melanoma involves combination BRAF 
and MEK inhibitors to target inhibition of the MAPK 
pathway. Due to the aggressiveness of melanoma and 
its unique ability to develop resistant mutations even 
after treatment with combination of BRAF and MEK 
inhibitors, it will become necessary to develop alter-
native forms of therapy to evade resistance. Our study 
demonstrated that targeting glutamine metabolism 
can be a way to potentially treat vemurafenib resistant 
melanoma.
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